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The c.151C>T founder mutation in COCH is a frequent cause of
late-onset, dominantly inherited hearing impairment and vestib-
ular dysfunction (DFNA9) in theDutch/Belgian population. The
initial clinical symptoms only manifest between the 3rd and 5th
decade of life, which leaves ample time for therapeutic interven-
tion. The dominant inheritance pattern and established non-
haploinsufficiency disease mechanism indicate that suppressing
translation ofmutantCOCH transcripts has high therapeutic po-
tential. Single-molecule real-time (SMRT) sequencing resulted in
the identification of 11 variants with a low population frequency
(<10%) that are specific to the c.151C>T mutant COCH allele.
Proof of concept was obtained that gapmer antisense oligonucle-
otides (AONs), directed against the c.151C>T mutation or
mutant allele-specific intronic variants, are able to inducemutant
COCH transcript degradation when delivered to transgenic cells
expressing COCH minigenes. The most potent AON, directed
against the c.151C>T mutation, was able to induce a 60%
decrease in mutant COCH transcripts without affecting wild-
type COCH transcript levels. Allele specificity decreased when
increasing concentrations of AON were delivered to the cells.
With the proven safety of AONs in humans, and rapid advance-
ments in inner ear drug delivery, our in vitro studies indicate that
AONs offer a promising treatment modality for DFNA9.
INTRODUCTION
DFNA9, caused by mutations in the COCH gene, is a relatively com-
mon form of dominantly inherited highly progressive hearing loss
and vestibular dysfunction. It is characterized by adult-onset hearing
loss, leading to complete deafness by the age of 50–70 years.1,2 With
progression of the disease, speech perception and conversation
become severely limited. DFNA9 patients furthermore suffer from
balance problems, which severely hamper their daily activities. Over-
all, the problems associated with DFNA9 have a severe impact on the
quality of life of patients and their relatives and friends.3
The COCH gene is located on chromosome 14, and encodes cochlin, a
protein that consists of 550 amino acids. Cochlin is predicted to
contain a signal peptide, an LCCL (limulus factor C, Cochlin, and
late gestation lung protein Lgl1) domain, two short intervening do-
mains, and two vWFA (von Willebrand factor A) domains. Cochlin
is expressed in fibrocytes of the spiral ligament and spiral limbus,
where it has been reported to assist in structural support and sound
processing, and in the vestibular fibrocytes that are important in
the maintenance of balance.4 Proteolytic cleavage of cochlin, between
the LCCL domain and the more C-terminal vWFA domains, results
in a 16-kDa LCCL domain-containing peptide that is secreted and
has been shown to play a role in innate immunity in the cochlea.5
The vWFA domain-containing cochlin fragments are presumed to
be extracellular matrix proteins, as cochlin vWFA2 was found to
interact with collagens in vitro, and cochlin is a major component
of the cochlear extracellular matrix.1,6
The c.151C>T (p.Pro51Ser) founder mutation, affecting the LCCL
domain, appears to be themost prevalent mutation inCOCH, as it un-
derlies hearing loss in >1,000 Dutch and Belgian individuals.7,8 His-
topathology of a temporal bone from a p.Pro51Ser DFNA9 patient re-
vealed significant loss and degeneration of fibrocytes in the cochlea.1
Overexpression of murine cochlin containing the ortholog of the
p.Pro51Ser variant in cultured cells previously revealed that this mu-
tation results in the formation of cytotoxic cochlin dimers and oligo-
mers that sequester wild-type cochlin.9 While the proteolytic cleavage
of cochlin was shown to be reduced by the p.Pro51Ser variant and
abolished by several other DFNA9-associated variants,9 the potential
contribution of decreased proteolytic cleavage to DFNA9 pathology
requires further investigation.
All available data indicate that DFNA9 results from a gain-of-func-
tion and/or a dominant-negative disease mechanism, rather than
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from haploinsufficiency. Downregulation of the mutant allele,
thereby alleviating the inner ear from the burden caused by the for-
mation of cytotoxic cochlin dimers, therefore has high therapeutic
potential. The lack of auditory and vestibular phenotypes in mice car-
rying a heterozygous protein-truncating mutation in Coch,10 and in
heterozygous family members of patients with early-onset hearing
impairment due to homozygous protein-truncating mutations in
COCH,11 illustrate that sufficient functional cochlin proteins can be
produced from a single healthy COCH allele. We speculate that a
timely intervention might even prevent hearing impairment
altogether.
Antisense oligonucleotides (AONs) with DNA-like properties can be
employed to target (pre-)mRNA molecules for degradation by the
RNase H1 endonuclease.12,13 Chemical modifications can be intro-
duced in the 50 and 30 flanking nucleotides to increase stability and
nuclease resistance, while maintaining a central gap region of oligo-
deoxynucleotides to bind to the target RNA and thereby activate
RNase H1.12 These AONs are named gapmers, and their ability to
specifically target mutant alleles for degradation has shown great
promise in treatment strategies for non-haploinsufficiency disorders
such as Huntington’s disease.14,15
For a successful application of AON therapy for non-haploinsuffi-
ciency disorders such as DFNA9, it is of major importance that the
designed AONs only target the mutant (pre-)mRNA, and not the
wild-type (pre-)mRNA, for degradation. As the options to design
allele-discriminating AONs based on a single nucleotide difference
are limited, we used single-molecule real-time (SMRT) sequencing
to identify additional allele-discriminating variants that can be ex-
ploited for AON design. This resulted in the identification of 11 var-
iants with a low population frequency (<10%) that are specific to the
c.151C>T mutant COCH haplotype. Our results show that both the
c.151C>T mutation in COCH and low-frequency variants in cis
with the DFNA9 mutation can be used to specifically target mutant
COCH transcripts for degradation by RNase H1. Lead molecule
c.151C>T AON-E appears to be the most promising molecule for
further preclinical investigation. As this AON targets the DFNA9-
causing mutation, future clinical application is not limited by the po-
tential presence of the target on the patient’s wild-type allele.
RESULTS
Identification of therapeutic targets
In order to develop a mutant-allele-specific therapy for DFNA9, reli-
able discrimination between the mutant and the wild-type allele is of
vital importance. However, the single-nucleotide changes in COCH
underlying most cases of DFNA9 restrict the design of allele-discrim-
inating therapies. In search of additional variants that can be ex-
ploited to improve discrimination between the c.151C>T mutant
and wild-type COCH allele, we subjected the genomic COCH
sequence of three DFNA9 patients to long-read SMRT sequencing.
We amplified the COCH gene in three fragments that contain over-
lapping single-nucleotide polymorphisms (SNPs) (c.151C>T and
c.734-304T>G) to aid haplotype assembly (Figure 1A). The identified
variants are annotated on transcript NM_001135058.1, which does
not contain the extended second coding exon. To identify targetable
allele-specific variants that potentially allow for the treatment of the
majority of the Dutch/Belgian DFNA9 patients, we filtered the vari-
ants in cis with the c.151C>T mutation for a population frequency
below 20%. This resulted in the identification of 11 deep-intronic var-
iants that are specific for the c.151C>T mutant COCH allele and have
population frequencies between 5% and 10% (Figure 1B; Table 1).
The identified variants provide additional targets for the development
of a mutant allele-specific genetic therapy. The identified variants
were validated using Sanger sequencing and confirmed to segregate
with the c.151C>T mutation in COCH in two branches of Dutch
DFNA9 families (Figure S1).
Design and in silico analysis of AONs
We selected the c.151C>T founder mutation and the intronic,
mutant-allele-specific variant c.436+368_436+369dupAG as targets
for AON-based therapy. In contrast with the identified single-
A
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Figure 1. COCH haplotype analysis
(A) Overview of the amplicons used to determine the haplotype-specific variants on the c.151C>T mutant COCH allele. Amplicon length is indicated in base pairs (bp)
between brackets. (B) Variants with a low population frequency (<10%) on the c.151C>T mutant haplotype. The six identified variants in intron 7 are 1: c.629+1186T>C; 2:
c.629+1779delC; 3: c.629+1807delA; 4: c.629+1809A>C; 5: c.629+1812A>T; 6: c.630-208A>C. Intron-exon structure of transcript NM_001135058.1 is depicted. The
c.151C>T variant, causative for DFNA9, is indicated in bold.
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nucleotide changes or deletions, the c.436+368_436+369dupAG
variant is the only multi-nucleotide variant that is specific to the
mutant allele. Based on this, we hypothesized that AONs directed
against this variant can provide the highest allele specificity. To design
AONs, we combined the criteria that are commonly used to design
splice-switching AONs with the previously established notion that
RNase H1-dependent AONs require a series of nucleotides with
DNA-like properties in their central region.16–18 All possible AONs
were investigated for thermodynamic properties in silico, with partic-
ular attention to the difference in binding affinity between the mutant
and wild-type COCH mRNA. Targeting regions of all AONs used in
this study are shown in Figure 2A. Note that the difference in binding
affinity between the mutant and wild-type COCH mRNA was pre-
dicted to be larger for the AONs directed against the dupAG variant
(c.436+368_436+369dupAG) compared to those directed against the
single nucleotide substation (c.151C>T) (Table S1). The recognition
of RNA/DNA duplexes by RNase H1 relates to the nature of the car-
bohydrate moiety in the AON backbone (20-ribose versus 20-deoxyri-
bose).16 Therefore, AONs were either comprised completely of phos-
phorothioate (PS)-linked DNA bases, or of a central “gap” region of
PS-DNA bases flanked by wings of 20-O-methyl-RNA bases
(gapmers). The gapmer design is particularly suitable for clinical
application, as the nuclease-resistant 20-modified ribonucleotides
provide an increased binding affinity and half-life time.12,19,20
Establishing stable transgenic cell lines expressing wild-type or
c.151C>T COCH minigenes
The COCH expression levels in patient-derived primary fibroblast
and Epstein-Barr virus-transformed lymphoblastoid cells are too
low to reliably determine the effect of RNase H1-dependent AONs.
Therefore, we used the Flp-In system to generate two stable trans-
genic T-REx 293 cell lines, expressing either amutant (including three
deep-intronic allele-discriminating variants; Figure 1) or a wild-type
COCHminigene construct under the control of a tetracycline-depen-
dent promotor. The minigene constructs span the genomic COCH
sequence between the transcription initiation site and the last com-
plete nucleotide triplet of exon 7 (Figure S2A). For both alleles, several
clones were expanded and investigated for inducible COCH expres-
sion (Figure S2B). Correct pre-mRNA splicing of both wild-type
and mutant minigene COCH exons 1–7 was confirmed with RT-
PCR (Figure S2C). In order to reliably quantify mutant and wild-
type COCH transcript levels, we used a custom TaqMan assay
(Applied Biosystems), in which different fluorophores are coupled
to probes specific for either the mutant or the wild-type transcript.
RNase H1-dependent AONs target mutant COCH transcripts for
degradation
As the COCH gene is continuously expressed in the human cochlea,
we opted for an experimental design in whichCOCH transcription re-
mains active. To induce COCH transcription, seeded cells were
treated overnight with tetracycline (0.25 mg/mL). Next morning, cul-
ture medium was replaced by fresh tetracycline-containing medium,
and cells were transfected with the AONs. For the initial screening of
AONs, we transfected AONs (n = 1) to a final concentration in the
culture medium of 250 nM. This dose was selected based on the
work of Naessens et al.,21 who showed a 50%–70% decrease in target
transcripts in an overexpression-based cell model to identified candi-
date AONs for the future treatment ofNR2E3-associated retinitis pig-
mentosa. Six (out of seven) AONs directed against the c.151C>T mu-
tation (Figure 2B) and four (out of seven) AONs directed against the
dupAG variant (Figure 2C) were able to decrease the level of mutant
COCH transcripts as compared to a scrambled control AON.
Three of the most effective AONs directed against the c.151C>T mu-
tation, and one AON directed against the dupAG variant, were
analyzed in more detail using different concentrations of gapmer
Table 1. Identified low-frequency variants on the c.151C>T COCH haplotype
Location SNP identifier Nucleotide change (HGVS) Amino acid change
Frequency (percentage) gnomAD European non-
Finnish
e4 rs28938175 c.151C>T Pro51Ser T: 0.0032
i4 rs143609554 c.240-239A>T T: 5.4
i6 rs7140538 c.436+185G>T T: 5.5
i6 rs10701465 c.436+368_436+369dupAG dupAG: 5.5
i8 rs186627205 c.629+1186T>C C: 5.4
i8 rs200080665 c.629+1779delC delC: 5.4
i8 rs368638521 c.629+1807delA delA: 5.9a
i8 rs554238963 c.629+1809A>C C: 9.9a
i8 rs184635675 c.629+1812A>T T: 5.4
i8 rs2295128 c.630-208A>C C: 5.3
i9 rs28362773 c.734-304T>G G: 7.2
i11 rs17097458 c.1477+9C>A A: 5.4
HGVS, Human Genome Variant Society.
aNo data in gnomAD; frequency data from dbSNP 153.
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AONs and multiple technical replications (Figure 3). c.151C>T
AON-A was able to induce a significant decrease in mutant COCH
transcripts at a dose of 250 nM (p = 0.02, Tukey’s multiple compar-
ison test), but not at 100 nM (Figure 3A). While AON-B showed a
stronger effect in comparison to AON-A in the initial screening,
the effect sizes of AON-A and -B were very similar in this replication
experiment (Figure 3B). A significant decrease of mutant COCH tran-
scripts was found at 100 nM and 250 nM (p < 0.0012, Tukey’s mul-
tiple comparison test). The third AON directed against the
c.151C>T mutation that was investigated in more detail, AON-E,
did show a typical dose-dependent decrease in mutant COCH tran-
script levels. At 100 nM, the level of mutant COCH transcripts was
approximately half of the number of transcripts detected in cells
treated with a scrambled control AON (p < 0.0002, Tukey’s multiple
comparison test). Mutant COCH transcript levels were even further
decreased in cells transfected with 250 nM of AON-E (p < 0.0001, Tu-
key’s multiple comparison test). While on average the AONs directed
against the dupAG variants appeared slightly less effective in the
initial AON screen, transfection of mutant COCH-minigene-express-
ing cells with dupAG AON-B resulted in a significant decrease in
mutant COCH transcripts at the three concentrations tested (Fig-
ure 3D; p < 0.0009, Tukey’s multiple comparison test). The highest
effect size appears already to be achieved at 25 nM. The maximum ef-
fect size of dupAG AON-B was similar to the effect observed for
c.151C>T AON-A and -B, but it was much less when compared to
c.151C>T AON-E.
We next investigated the ability of these four AONs in discriminating
between mutant and wild-type COCH transcripts (Figure 4). We
chose to compare the AONs at a concentration of 100 nM, as three
out of the four AONs were able to significantly reduce mutant
COCH transcript levels at this concentration. As observed previously,
transfection of mutant COCHminigene cells with c.151C>T AON-B,
c.151C>T AON-E, and dupAG AON-B significantly decreased
mutant COCH transcript levels as compared to a scrambled control
AON (Figure 4A). None of the four AONs induced a significant
decrease of wild-type COCH transcripts when transfected in wild-
type COCH-expressing transgenic cells, although we did observe a
marked decrease in both mutant and wild-type COCH transcript
levels resulting from the transfection of c.151C>T AON-A (Fig-
ure 4B). Likely, the correction for multiple comparisons explains
the lack of a significant difference between c.151C>T AON-A-treated
and scrambled AON-treated wild-type COCH minigene cells.
While both cell lines display the same tetracycline-induced 18-fold in-
crease in COCHminigene expression (Figure 4, left y axis), the expres-
sion levels relative to housekeeping gene RPS18 differ between clones
(Figure 4, right y axis). The higher normalized expression of wild-
A
B C
Figure 2. Design and identification of candidate AONs directed against the c.151C>T mutation and the in cis intronic variant c.436+368_436+369dupAG
(A) Graphical representation of AON-RNA binding positions on the c.151C>TmutantCOCH transcript. Coding sequences are shown in capitals, intronic sequences in lower
case. AON sequences are provided in Table S1. (B) Degradation of mutant COCH transcripts by AONs (250 nM end concentration in the medium), directed against the
c.151C>T mutation, in mutant COCH-expressing transgenic cells. Six out of the seven AONs were able to lower the levels of mutant COCH transcripts at 24 h post
transfection as compared to cells transfectedwith a scrambled control AON. (C) Degradation of mutantCOCH transcripts by different AONs (250 nM end concentration in the
medium), directed against the c.436+368_436+369dupAG variant on themutantCOCH transcript, inmutantCOCH-expressing transgenic cells. Four out of the seven AONs
showed an obvious decrease in mutant COCH transcript levels at 24 h post transfection as compared to cells transfected with a scrambled control AON. Uninduced and
scrambled controls are displayed as the average of three biological replicates. Single transfections are used for the screening of on-target AONs. Data are displayed as the
fold change compared to scrambled control AON-treated cells and normalized for the expression of RPS18.
www.moleculartherapy.org
Molecular Therapy: Nucleic Acids Vol. 24 June 2021 277
type COCHminigene transcripts as compared to mutant COCHmini-
gene transcriptsmay lead to an overestimation of allele specificity of the
AONs. Furthermore, the lack ofmutantCOCH transcripts in these cells
poorly resembles the situation in patients. To better determine allele
specificity, we searched for a mutant COCH minigene clone with
similar expression levels of tetracycline-induced mutant COCH mini-
gene and endogenous (wild-type)COCH. Subjecting these cells to three
different AON concentrations revealed that c.151C>T AON-E can
induce a significant and allele-specific reduction inmutantCOCH tran-
script level at 25 nM (Figure 5A) (p < 0.0001, Tukey’s multiple compar-
ison test). At 100 nM and 250 nM, c.151C>T AON-E induces a
concomitant decrease in endogenous wild-type COCH levels. Never-
theless, the 4- to 6-fold lower levels of mutant COCH transcripts as
compared to wild-type COCH transcripts indicate that c.151C>T
AON-E has a stronger affinity for the mutant transcript. In the same
cell model, transfection of 25 nM of dupAG AON-B did not result in
significant differences in mutant and wild-type COCH transcript levels
(Figure 5B). A scrambled control AONwas included in this experiment
to confirm that the observed effect is specific to the AON sequence.
Transfection of the cells with the scrambled AON mildly increases
endogenous wild-type COCH expression but not the expression of
the tetracycline-inducedmutant COCHminigene. Although compared
to the delivery of scrambled AON, c.151C>T AON-E does reduce the
levels of wild-type COCH transcripts with 30% (p = 0.14, Tukey’s mul-
tiple comparison test), the comparison with untransfected cells ex-
pressing both mutant and wild-type COCH transcripts is most relevant
from a therapeutic point of view.
DISCUSSION
The c.151C>T founder mutation inCOCH is estimated to be one of the
most prevalent causes of dominantly inherited, adult-onset hearing loss
and vestibular dysfunction in Northwest Europe, affecting >1,000 indi-
viduals in theDutch/Belgian population. In this work, we present 11 in-
tronic variants in cis with the c.151C>T mutation and show that these
variants can be exploited for the development of amutant-allele-specific
therapyusingRNaseH1-dependentAONs.We identifiedahighly effec-
tive AON, directed against the c.151C>T mutation, as the most prom-
ising candidate for further preclinical development.
The ability of AONs to specifically target mutant transcripts for degra-
dation is of key importance for the development of anAON-based ther-
apy for dominantly inherited disorders with a dominant-negative or
gain-of-function disease mechanism such as DFNA9. The therapeutic
strategy must be potent enough to prevent the synthesis of proteins
from the mutant allele but allow sufficient protein synthesis from the
wild-type allele for normal inner ear function. For any antisense-based
approach, discrimination between alleles based on a single-nucleotide





Figure 3. Identified candidate AONs induce a
significant decrease in mutant COCH transcript levels
(A–D) To confirm the effect of previously identified candidate
AONs, c.151C>T AON-A (A), c.151C>T AON-B (B),
c151C>T AON-E (C), and c.436+368_436+369dupAGAON-
B (D) were investigated at two different doses. (A) c.151C>T
AON-A results in significant decrease in mutant COCH
transcripts at 250 nM, but not at 100 nM. (B) c.151C>T AON-
B was able to induce a significant decrease in mutant COCH
transcripts at both 100 nM and 250 nM, but no differences
between the two doses were observed. (C) c.151C>T AON-E
decreased the level of mutant COCH transcripts in a statis-
tically significant and dose-dependent manner. At a con-
centration of 250 nM, the number of COCH transcripts was
reduced to 20% of those in cells treated with a scrambled
control AON. (D) Transfection of c.436+368_436+369dupAG
AON-B resulted in a significant decrease of mutant COCH
transcripts, without statistically relevant differences between
the two concentrations. All four AONs had a gapmer design
with wings of 20-O-methyl-RNA bases flanking the central
PS-DNA core. AONs were transfected at a dose leading to
the indicated concentration in the well and investigated for
their effect on transcript levels 24 h after transfection. Data are
expressed as mean ± SD of 3 replicate transfections,
normalized to the expression of RPS18 and displayed as the
fold change compared to scrambled control AON-treated
cells. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-
way ANOVA with Tukey’s post-test.
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downregulation of the wild-type allele.22–24 Recently published AONs
directed against a mutation in NR2E3, causative for dominantly in-
herited retinitis pigmentosa, also significantly reduced the wild-type
transcript and protein levels.21 In contrast, for Huntington’s disease
(HTT gene), also resulting fromanon-haploinsufficiency diseasemech-
anism, the use of gapmer AONs to target a SNP specific to the mutant
allele emerged as a promising therapeutic strategy in vitro and in vivo.15
As nearly all cases of DFNA9 are caused by single-nucleotide changes,25
we explored the presence of mutant-allele-specific variants that can
serve as additional targets to develop a therapeutic strategy for the
most frequently occurring DFNA9 mutation, c.151C>T. Here, we em-
ployed SMRT sequencing26 to sequence the complete mutant COCH
haplotype using three overlapping PCR amplicons. With average poly-
merase read lengths of up to 30 kb, the SMRT sequencing platform pre-
sents a powerful tool to identify genetic variants on themutant allele and
offers a major advantage over the manual genotyping of family trios, as
done for example to identify the target SNPs in the HTT gene.27
The c.151C>TCOCH allele contains a remarkablyhighnumberof SNPs
with a relatively low allele frequency (5%) in the non-Finnish Euro-
pean population according to the gnomAD database (v.2.1.1).28 As
the c.151C>T foundermutation arose on a relatively uncommonhaplo-
type, we estimate that less than 5% of DFNA9 patients are homozygous
for these SNPs. Therefore, approximately 95% of DFNA9 patients with
the c.151C>Tmutation can theoretically be treatedwith AONs directed
against one of these mutant-allele-specific variants. In comparison, it
was reported that targeting one of three relatively frequent SNPs can
provide a treatment for approximately 85% of patients suffering from
Huntington’s disease.27 In contrast to the identified mutant-allele-spe-
cific SNPs inHTT, all of the identified variants inCOCHmap to the in-
trons. As such, the identified mutant-allele-specific variants in COCH
are only amenable to AON-mediated pre-mRNA degradation by the
RNase H1 enzyme and not to mRNA interference (RNAi).29–31
We designed AONs to specifically target mutant COCH transcripts for
RNase H1 degradation. In addition to targeting the DFNA9-associated
mutation c.151C>T, we opted to target the 2 bp duplication c.436-
+368_436+369dupAG in cis with the DFNA9 mutation. In silico anal-
ysis of thermodynamic AON properties indicated that AONs directed
against the dupAG variant possess a larger difference in binding affinity
between themutant and the wild-type transcript as compared to AONs
directed against the c.151C>T mutation (Table S1). The on-target effi-
cacy of AONs was investigated in stable transgenic cells that express a
mutant COCH minigene under control of a tetracycline-dependent
promotor. A similar cell model was previously used to investigate the
kinetics of RNase H1-dependent antisense oligonucleotide induced
degradation13 and offers a suitable alternative to the patient-specific
fibroblast and lymphoblastoid cell lines that hardly express COCH.
We opted to investigate the effect of AONs under continuous activation
of COCH transcription, which best resembles the situation in the co-
chlea, where constant COCH expression amounts to synthesis of one
of the most abundant proteins in the entire organ.1,6 The gapmer
configuration of c.151C>T AON-E was the most effective of all the de-
signed AONmolecules and at the highest dose resulted in a decrease of
mutant COCH transcripts to <15% of the number of transcripts in cells
treated with a scrambled control AON. The effects of AONs directed
against the c.436+368_436+369dupAG (dupAG) variant were overall
lower as compared to the c.151C>T AONs. This could result from
small differences in biochemical properties. The target region of the du-
pAG variant is more AT rich as compared to the sequence surrounding
the c.151C>T variant. The calculated free energy of on-target AON
A
B
Figure 4. Comparison of AON efficiency in mutant and wild-type COCH-
minigene-expressing cells
(A and B) AONs directed against the c.151C>T mutation or the c.436+368_436-
+369dupAG (dupAG) variantwere transfected in stable transgenic cell lines expressing
(A) a mutant COCH minigene, and (B) a wild-type COCH minigene. AONs were
transfected at a dose that results in a final concentration of 100 nM in the culture
medium, and their effect on COCH transcript levels was investigated 24 h post
transfection. (A) As shown previously, c.151C>T AON-B and AON-E, and dupAG
AON-B,wereable to induceasignificantdecrease in themutantCOCH transcript level.
(B) None of the AONs resulted in a significant decrease in wild-type COCH transcript
levels in transgenic cells expressing the wild-type COCH minigene. While c.151C>T
AON-A results in a decrease in wild-type COCH transcript levels, the observed
decrease is not statistically significant (p = 0.14, Tukey’s multiple comparison test). All
AONs used here consisted of a gapmer composition. Mutant and wild-type COCH
transcript levels are normalized for the expression ofRPS18 and plotted asmean± SD
of 3 replicates. The left axis shows the fold change compared to scrambled AON-
transfected cells; the right axis shows the RPS18 normalized transcript levels. *p <
0.05, **p < 0.01, ***p < 0.001, one-way ANOVA with Tukey’s post-test.
www.moleculartherapy.org
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binding was indeed lower for AONs directed against the dupAG
variant as compared to AONs directed against the c.151C>Tmutation.
The fact that these AONs are directed against an intronic variant,
which is only present in unspliced nuclear pre-mRNA, could also
contribute to the lower on-target efficiency.
In terms of specificity for the mutant COCH allele, we anticipated an
advantage for AONs directed against the dupAG variant. When trans-
fected in wild-type COCH minigene-expressing cells, both c.151C>T
AON-E and dupAG AON-B did not reduce the levels of wild-type
COCH. In view of the higher expression of wild-type COCH as
compared to mutant COCH, we concluded that this approach could
possibly overestimate the allele specificity. We searched for a mutant
COCH minigene clone with similar (tetracycline induced) mutant
COCH expression as endogenous wild-type COCH expression. Trans-
fection of c.151C>T AON-E in these cells revealed that allele specificity
strongly depends on the amount of AON that is delivered to the cells. At
25 nM, the levels ofmutantCOCH transcripts were decreased to 40% of
the levels of mutant COCH in control cells, without reducing the num-
ber of wild-typeCOCH transcripts. Upon increasing the concentration,
c.151C>T AON-E also reduced the number of wild-type transcripts,
albeit less compared to the reduction in mutant transcript levels. While
dupAG AON-B also did not reduce wild-type COCH levels at 25 nM,
the effect onmutantCOCH transcriptswasmild and therefore currently
of little relevance for future clinical applications, especially since trans-
fections with increasing doses did not further decrease the levels of
mutant COCH transcripts in the initial dose-response study. While
the on-target efficiency of AONs directed against the dupAG variant
can be improved by, for example, increasing the length of the AON
or introducing chemically modified nucleotides that enhance binding
affinity, we see little reason for this. With higher efficiency and allele
specificity at 25 nM, c.151C>T AON-E is a better candidate for clinical
applications, especially since the use of AONs directed against the path-
ogenic mutations, unlike those directed against allele-specific variant, is
not constrained by a small percentage of individuals who are homozy-
gous for the target variant.
While c.151C>T AON-E could also benefit in terms of allele specificity
fromchemicalmodifications, decreasingAONlengthandor shortening
the gap region, these alternations are likely to decrease cleavage effi-
ciencyaswell. This raises the questionofhowmuch reduction inmutant
COCH transcripts is required to achieve a clinically meaningful effect.
Lacking an animal model to perform these experiments, we can
currently only discuss the different factors that will determine the ther-
apeutic effect. First of all, our data suggest that allele specificity strongly
depends on the expression levels of mutant and wild-type COCH.
Therefore, the AON dose is best titrated in vivo. In addition, we should
realize that the levels ofmutant andwild-typeCOCH are not necessarily
identical, as allelic variation in gene expression is quite common in the
human genome.32 Second, we do not know yet how much knockdown
of mutant COCH is required to alleviate the patient’s phenotype. The
age of onset of symptoms in DFNA9, usually between the 3rd and 5th
decade of life for the c.151C>Tmutation,2,33,34 indicates that the cochlea
can cope with the burden ofmutant cochlin proteins formany decades.
It has furthermore been shown that otic fibrocytes, the main cell type
producing cochlin, display some capacity for self-renewal.35 In the
most optimal situation, AONs might be able to remove the burden of
mutant cochlin proteins to an extent that allows for fibrocyte renewal
and thereby possibly improved auditory and vestibular function. We
speculate that a >50% reduction of mutant transcript levels, such as
achieved upon the transfection of 25 nM of c.151C>T AON-E, could
already be sufficient to halt or delay the disease progression when
A
B
Figure 5. Investigation of allele-specificity in cells with equal levels of
mutant and wild-type COCH transcription
Mutant COCH-minigene-expressing cells from a clone with comparable expression
levels of endogenous wild-typeCOCHwere transfected with AONs. (A) Transfection
of cells with c.151C>T AON-E results in a dose-depended decrease in mutant
COCH transcript levels. Allele-specific reduction of mutant COCH transcript levels
was observed at 25 nM but not at 100 and 250 nM. (B) Mutant and wild-type COCH
transcript levels in cells treated with 25 nM c.151C>T AON-E, dupAG AON-B, or
scrambled control AON. Mutant and wild-type COCH transcript levels are
normalized for the expression of RPS18 plotted as mean ± SD or 3 replicates. ***p <
0.001, two-way ANOVA with Tukey’s multiple-comparison post-test conducted for
possible comparisons. Outcome for relevant comparisons is shown; asterisks
indicate the p value compared to tetracycline-treated cells.
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treatments are started at an early stage. The third factor is the extent to
which a reduction inwild-typeCOCH transcripts is tolerated.We know
from animal models and carriers of loss-of-function mutations that the
number of wild-type transcripts from a single allele is sufficient for
normal inner ear function. While difficult to put a number on the min-
imal number of transcripts needed, studies on splice modulation ther-
apy for USH1C-associated hearing loss indicate that 20% of functional
USH1C transcripts is sufficient for inner ear function.36 Along these
lines, the 80% reduction of mutant transcripts and 50% reduction of
wild-type transcripts that we observe upon the transfection of 100 nM
c.151C>T AON-E could potentially yield good therapeutic outcomes.
The transient effect of AONs is both an advantage and a potential lim-
itation for future clinical applications. It lowers the risk of sustained
adverse or off-target effects that could accompany genome-editing
techniques, but it also implies that a repeated delivery is likely to be
required to achieve maximum efficacy. AON-based splice-modulation
therapy for hearing impairment in Usher syndrome type 1c is exten-
sively investigated in the fetal and post-natal cochlea.36,37 In contrast
to USH1C-associated hearing impairment, the adult age of onset of
DFNA9 leaves ample opportunity for therapeutic intervention in adults
before the onset of the initial symptoms. Delprat et al.38 previously re-
ported the use of phosphorothioate oligonucleotide-mediated knock-
down in the adult rodent cochlea to investigate the role of the otospir-
alin protein in the inner ear protein. In this study, they placed pieces of
gel foam loaded with AONs on the round window membrane (RWM)
of rats and observed the effects of otospiralin knockdown already
2 days later.38 Otospiralin and cochlin are both expressed by the otic
fibrocytes, which indicates that cellular uptake of AONs is unlikely to
be a limiting factor for future AON-based DFNA9 therapy. Although
many advancements in cochlear drug delivery have been made
since,39–41 a huge gap in knowledge remains in terms of safety, stability,
and biodistribution of gapmer AONs in the (adult) human cochlea.
Further investigation into the feasibly of RWM diffusion as a potential
delivery method for AON-based therapy in patients is also warranted,
as the gapmer composition of AONs may affect diffusion properties,
and the thickness of the human RWM and larger size of the cochlea
are likely to affect the biodistribution.
In conclusion, this study shows that AONs can be engineered to target
the c.151C>T mutant COCH transcript for degradation. The identi-
fied intronic, mutant-allele-specific variants present interesting alter-
native targets to design allele-specific AONs. However, the AONs
directed against the intronic variant in COCH that were investigated
here require further optimization of knockdown efficiency and spec-
ificity before continued preclinical development is warranted. The
best-performing AON directed against the pathogenic mutation is
able to reduce mutant COCH transcripts by 60% without affecting
levels of wild-type transcripts. While increasing AON concentration
further increased the reduction in mutant COCH transcripts, the
levels of wild-type transcripts no longer remain unaffected. Further
pre-clinical studies in animal models of DFNA9 are needed to assess
the clinically relevant reduction in mutant COCH transcript levels
and to what extent a decrease in wild-type transcripts is tolerated.
The rapidly evolving procedures for repeated drug delivery to the co-
chlea render the application of AONs for the treatment of inherited
hearing impairment an increasingly feasible strategy.
MATERIALS AND METHODS
SMRT sequencing of COCH haplotypes
This study was approved by the medical ethics committee of the Rad-
boud University Medical Center in Nijmegen, the Netherlands and
was carried out according to the Declaration of Helsinki. Experiments
were conducted at theRadboudUniversityMedical Center inNijmegen,
the Netherlands. Written informed consent was obtained from all par-
ticipants. DNA samples of three seemingly unrelated DFNA9 patients
carrying the c.151C>T mutation in COCH were selected for SMRT
sequencing (Pacific Biosciences, Menlo Park, CA, USA) to identify
shared variants on the mutant allele. The COCH gene was amplified
in three overlapping amplicons (Figure 1), in which known haplotype-
specific variants were anticipated to be present to aid assembly. Frag-
ments were amplified with primers 50-GAAGTTCGGTTCT
CAGGCC-30 and 50-TGCCATCGTCATACAAAAGG-30 (fragment
1), 50-CAAAATCTGGAATGGTATGGAAG-30 and 50-GATCAAA
TGCAGACCTAGCC-30 (fragment 2), and 50-TCCCCTGCAG
TACTTTTTGTC-30 and 50-GTAAGCCAGCTTACAATAACTC-30
(fragment 3), using Q5 polymerase (New England Biolabs, Ipswich,
MA, USA) according to manufacturer’s instructions. Amplicons were
pooled per sample, and library preparation was done according to pro-
tocol Procedure and Checklist—Preparing SMRTbell Libraries using
PacBio Barcoded Adapters for Multiplex SMRT Sequencing (Pacific
Biosciences, #100-538-700-02). Generation of polymerase-bound
SMRTbell complexes was performed using the Sample Setup option in
SMRTLink 6.0 (Pacific Biosciences), and sequencing was performed
onaSequel I systems (PacificBiosciences). Following the run, generation
of circular consensus reads (CCS) and mapping of these reads was per-
formed using SMRTLink 6.0. Bam files were loaded into the Sequence
Pilot software (JSIMedical Systems) to performvariant calling. The var-
iants were subsequently filtered to excluded homopolymers and homo-
zygous variants. The identified variantswith a low population frequency
(<10%) were considered as potential therapeutic targets and validated
using targeted Sanger sequencing. Segregation analysis in two branches
of large Dutch DNFA9 families (W02-006 and W00-330) was used to
confirm the presence of the identified variants on themutant haplotype.
Primers used in the segregation analyses are listed in Table S2.
AONs
AONs were designed using previously published criteria for splice-
modulating AONs.17,18 In summary, the sequences surrounding the
c.151C>T and c.436+368_436+369dupAG variants on the mutant
COCH allele were analyzed in silico for AON accessibility. The thermo-
dynamic properties of every possible 20-mer antisense oligonucleotide
were analyzed in silico for AON-AON duplex formation, the formation
of AON-target mRNA duplexes, and the formation of AON-wild-type
mRNA duplexes using the RNAstructure webserver.42 The uniqueness
of the AON target sequences was determined by BLAST analysis. The
seven most optimal AONs were purchased from Eurogentec (Liège,
Belgium) and dissolved in phosphate-buffered saline (PBS) before
www.moleculartherapy.org
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use. As a non-binding control, an AON with a scrambled nucleotide
sequence was also acquired. Sequences and AON chemistry are pre-
sented in Table S1.
Generation of transgenic COCH minigene cell lines
The genomic region of wild-type and c.151C>T mutant COCH exons
1 to 7 (transcript variant 1; NM_001135058.1), including the haplo-
type-specific variants, was amplified from the translation initiation
site to the splice donor site of exon 7 using primers 50-ATGTCCG-
CAGCCTGGATC-30 and 50-GGCTTGAACAAGGCCCACA-30.
The mutant and wild-type amplicons were subsequently cloned
into the pgLAP1 vector (Addgene plasmid #19702) using Gateway
cloning technology (Invitrogen, Carlsbad, CA, USA). Upon sequence
validation, COCH-containing pgLAP1 vectors were co-transfected
with pOGG44 (#V600520, Invitrogen), encoding Flp-Recombinase,
in FLp-in T-REx 293 cells (#R78007, Invitrogen) using polyethyleni-
mine. Cells in which the COCH sequence was stably integrated were
selected for using DMEM-AQ medium (Sigma Aldrich, Saint Louis,
MO, USA) supplemented with 10% fetal calf serum, 1% penicillin/
streptomycin, sodium pyruvate, 10 mg/mL blasticidin, and 100 mg/
mL hygromycin. Individual hygromycin-resistant clones were
expanded and subsequently tested for the induction of COCH tran-
scription by tetracycline using an allele-specific TaqMan assay. Cor-
rect splicing of the COCH minigenes was assessed using a forward
primer on exon 1 (50-TCCGCAGCCTGGATCCCGG-30) and reverse
primer on exon 7 (50-GGCTTGAACAAGGCCCACA-30).
Delivery of RNase H1-dependent AONs
Wild-type and mutant COCH-expressing FLp-in T-REx 293 cells
were cultured in DMEM-AQ medium (Sigma Aldrich, Saint Louis,
MO, USA) supplemented with 10% fetal calf serum, 1% penicillin/
streptomycin, sodium pyruvate, 10 mg/mL blasticidin, and 100 mg/
mL hygromycin. For AON treatments, cells were seeded in 12-well
or 24-well plates at50% confluency. Next day, COCH transcription
was activated through the administration of 0.25 mg/mL tetracycline
(#T7660, Sigma Aldrich). Twenty hours after induction, cells were
transfected with AONs using Lipofectamine 2000 (Invitrogen) ac-
cording to manufacturer’s instructions, using a 1:2 ratio of AON
(in mg) and lipofectamine reagent (in mL). AON doses are calculated
as final concentration in the culture medium. Cells were collected for
transcript analysis 24 h after AON delivery.
RNA extraction and cDNA synthesis
Total RNA was extracted from cells using the Nucleospin RNA mini
kit (#740955, Machery-Nagel) according to manufacturer’s instruc-
tions. First-strand cDNA was generated using iScript cDNA synthesis
reagents (Bio-Rad, Hercules, CA, USA) using a fixed amount of RNA
input (250 ng) in a 10 mL reaction volume. The obtained cDNA was
diluted four times and used for transcript analysis.
Analysis of COCH transcript levels
Diluted cDNA (4 mL) was used as input in an allele-specific TaqMan
assay using primers 50-GGACATCAGGAAAGAGAAAGCAGAT-30
and 50-CCCATACACAGAGAATTCCTCAAGAG-30, a wild-type
allele-specific VIC-labeled probe 50-CCCCCTGGGCAGAG-30 and
a mutant allele-specific FAM-labeled probe 50-CCCCCTGAGCA-
GAG-30. Expression of RPS18 was analyzed with GoTaq (#A6002,
Promega), using primers 50-ATACAGCCAGGTCCTAGCCA-30
and 50-AAGTGACGCAGCCCTCTATG-30. Abundance of mutant
and wild-type COCH transcripts was calculated relative to the expres-
sion of the housekeeping gene RPS18.
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